Non-covalent inhibitors of the 20S proteasome

被引：1

作者：

García-Echeverría, C ^{[1
]}

Imbach, P ^{[1
]}

Roesel, J ^{[1
]}

Fuerst, P ^{[1
]}

Lang, M ^{[1
]}

Guagnano, V ^{[1
]}

Noorani, M ^{[1
]}

Zimmermann, J ^{[1
]}

Furet, P ^{[1
]}

机构：

[1] Novartis Pharma AG, Oncol Res, CH-4002 Basel, Switzerland

来源：

CHIMIA | 2003年 / 57卷 / 04期

关键词：

antitumor agents; drug design; enzyme inhibitors; peptidomimetic;

D O I：

10.2533/000942903777679415

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Peptidomimetics have been commonly used as lead compounds to design inhibitors with high affinity and specificity for a particular enzyme. The discovery that a 2-aminobenzylstatine derivative originally designed to target an aspartyl protease was able to inhibit specifically and non-covalently the chymotrypsin-like activity of the 20S proteasome represented a unique starting point for our medicinal chemistry endeavor for this target. Utilizing a structure-based design approach, we have been able to improve the potency of this new class of proteasome inhibitors without affecting its in vitro selectivity profile.

引用

页码：179 / 181

页数：3

共 50 条

[31] Metabolism guided optimization of peptidomimetics as non-covalent proteasome inhibitors for cancer treatment
Cao, Yu
Tu, Yutong
Fu, Liping
Yu, Qian
Gao, Lixin
Zhang, Mengmeng
Zeng, Linghui
Zhang, Chong
Shao, Jiaan
Zhu, Huajian
Zhou, Yubo
Li, Jia
Zhang, Jiankang
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 233
[32] 20S proteasome and its inhibitors: Crystallographic knowledge for drug development
Borissenko, Ljudmila
Groll, Michael
CHEMICAL REVIEWS, 2007, 107 (03) : 687 - 717
[33] Inhibitors of the Eukaryotic 20S Proteasome Core Particle: a Structural Approach
Groll, Michael
ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2005, 61 : C119 - C119
[34] Cystargolides, 20S Proteasome Inhibitors Isolated from Kitasatospora cystarginea
Gill, Krista A.
Berrue, Fabrice
Arens, Jennifer C.
Carr, Gavin
Kerr, Russell G.
JOURNAL OF NATURAL PRODUCTS, 2015, 78 (04): : 822 - 826
[35] Analogues of SFTI-1 as the potential inhibitors of the 20S proteasome
Debowski, D.
Mizeria, A.
Lesner, A.
Legowska, A.
Rolka, K.
JOURNAL OF PEPTIDE SCIENCE, 2012, 18 : S92 - S92
[36] Pharmacologic evaluation of orally bioavailable inhibitors of the 20S proteasome.
Kirk, Christopher J.
Aujay, Monette A.
Ho, Mark
Jiang, Jing
Laidig, Guy J.
Lewis, Evan R.
Lu, Yan
Muchamuel, Tony
Woo, Tina M.
Sun, Congcong M.
Sylvain, Catherine
Yang, Jinfu
Zhou, Han-jie
Bennett, Mark K.
BLOOD, 2006, 108 (11) : 1023A - 1023A
[37] Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach
Groll, M
Huber, R
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2004, 1695 (1-3): : 33 - 44
[38] Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors
Zhuang, Rangxiao
Gao, Lixin
Lv, Xiaoqing
Xi, Jianjun
Sheng, Li
Zhao, Yanmei
He, Ruoyu
Hu, Xiaobei
Shao, Yidan
Pan, Xuwang
Liu, Shourong
Huang, Weiwei
Zhou, Yubo
Li, Jia
Zhang, Jiankang
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 126 : 1056 - 1070
[39] The 20S proteasome of Streptomyces coelicolor
Nagy, I
Tamura, T
Vanderleyden, J
Baumeister, W
De Mot, R
JOURNAL OF BACTERIOLOGY, 1998, 180 (20) : 5448 - 5453
[40] Redox control of 20S proteasome
Friguet, B
Bulteau, AL
Conconi, M
Petropoulos, I
REDOX CELL BIOLOGY AND GENETICS, PT B, 2002, 353 : 253 - 262

← 1 2 3 4 5 →